Clinical and molecular characteristic of patients with trisomy 12
| Characteristic . | Value . |
|---|---|
| Level of ZAP-70 expression, no. patients | |
| ≤ 20% | 11 |
| > 20% | 5 |
| IGVH mutation status, no. patients | |
| Unmutated (≥ 98% homology) | 5 |
| Mutated (< 98% homology) | 11 |
| Trisomy 12–positive cells (%), median | 60 |
| Therapy not begun | |
| No. patients | 7 |
| Median time since sample data, mos | 28 |
| Therapy begun | |
| No. patients | 9 |
| Median TTT, mos | 19 |
| Characteristic . | Value . |
|---|---|
| Level of ZAP-70 expression, no. patients | |
| ≤ 20% | 11 |
| > 20% | 5 |
| IGVH mutation status, no. patients | |
| Unmutated (≥ 98% homology) | 5 |
| Mutated (< 98% homology) | 11 |
| Trisomy 12–positive cells (%), median | 60 |
| Therapy not begun | |
| No. patients | 7 |
| Median time since sample data, mos | 28 |
| Therapy begun | |
| No. patients | 9 |
| Median TTT, mos | 19 |
IGVH indicates immunoglobulin heavy chain variable-region; TTT, time to treatment; and ZAP-70, ζ-associated protein 70.